The DOI matches its Crossref record; 212 of the 212 references it cites were found in a registry or an index.
Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy
Abstract
The phosphatidylinositol 3-kinase (PI3K)-Akt and the mammalian target of rapamycin (mTOR) represent two vital intracellular signaling pathways, which are associated with various aspects of cellular functions. These functions play vital roles in quiescence, survival, and growth in normal physiological circumstances as well as in various pathological disorders, including cancer. These two pathways are so intimately connected to each other that in some instances these are considered as one unique pathway crucial for cell cycle regulation. The purpose of this review is to emphasize the role of PI3K-Akt-mTOR signaling pathway in different cancer conditions and the importance of natural products targeting the PI3K-Akt-mTOR signaling pathway. This review also aims to draw the attention of scientists and researchers to the assorted beneficial effects of the numerous classes of natural products for the development of new and safe drugs for possible cancer therapy. We also summarize and critically analyze various preclinical and clinical studies on bioactive compounds and constituents, which are derived from natural products, to target the PI3K-Akt-mTOR signaling pathway for cancer prevention and intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
RETRACTED: Downstream effectors of oncogenic ras in multiple myeloma cells
Hu, L., Shi, Y., Hsu, J.-H., Gera, J., Ness, B. V., & Lichtenstein, A. K. (2003) · Blood · doi:10.1182/blood-2002-08-2640 · Cited by 141
RetractedJiang, H., Li, J., Chen, A., Li, Y., Xia, M., Guo, P., Yao, S., & Chen, S. (2018) · Oncology Letters · doi:10.3892/ol.2018.7769 · Cited by 56
RetractedBray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61728-0 · Cited by 14,070
AKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
Natural products as sources of new drugs over the last 25 years
Newman, D. J., & Cragg, G. M. (2007) · Journal of Natural Products · doi:10.1021/np068054v · Cited by 5,517
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Cellular survival: a play in three Akts
Datta, S. R., Brunet, A., & Greenberg, M. E. (1999) · Genes & Development · doi:10.1101/gad.13.22.2905 · Cited by 4,216
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941
Integrative Genomic Profiling of Human Prostate Cancer
Taylor, B. S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E., Reva, B., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.026 · Cited by 3,701
The Molecular Taxonomy of Primary Prostate Cancer
Abeshouse, A., Ahn, J., Akbani, R., Ally, A., Amin, S., Andry, C. D., Annala, M., Aprikian, A., Armenia, J., Arora, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.10.025 · Cited by 3,110
Discovery and resupply of pharmacologically active plant-derived natural products: A review
Atanasov, A. G., Waltenberger, B., Pferschy-Wenzig, E.-M., Linder, T., Wawrosch, C., Uhrin, P., Temml, V., Wang, L., Schwaiger, S., Heiss, E. H., et al. (2015) · Biotechnology Advances · doi:10.1016/j.biotechadv.2015.08.001 · Cited by 2,904
The PI3K Pathway in Human Disease
Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017) · Cell · doi:10.1016/j.cell.2017.07.029 · Cited by 2,749
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019
Basic and Clinical Pharmacology
Katzung, B. G. (1982) · Andalas University Repository (Andalas University) · Cited by 1,914
Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer
Ciriello, G., Gatza, M. L., Beck, A. H., Wilkerson, M. D., Rhie, S. K., Pastore, A., Zhang, H., McLellan, M., Yau, C., Kandoth, C., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.033 · Cited by 1,858
PI3K and cancer: lessons, challenges and opportunities
Fruman, D. A., & Rommel, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4204 · Cited by 1,709
Targeting PI3K/Akt/mTOR Signaling in Cancer
Porta, C., Paglino, C., & Mosca, A. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00064 · Cited by 1,485
PI3K/AKT/mTOR Pathway in Angiogenesis
Karar, J., & Maity, A. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00051 · Cited by 1,461
Fruman, D. A., Meyers, R. E., & Cantley, L. C. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.481 · Cited by 1,355
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting
Thorpe, L. M., Yuzugullu, H., & Zhao, J. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3860 · Cited by 1,345
Carver, B. S., Chapinski, C., Wongvipat, J., Hieronymus, H., Chen, Y., Chandarlapaty, S., Arora, V. K., Le, C., Koutcher, J., Scher, H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.008 · Cited by 1,198
Basic and clinical pharmacology
Traynor, J. R. (1988) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/0731-7085(88)80021-9 · Cited by 1,126
The LKB1 tumor suppressor negatively regulates mTOR signaling
Shaw, R. J., Bardeesy, N., Manning, B. D., Lopez, L., Kosmatka, M., DePinho, R. A., & Cantley, L. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.007 · Cited by 1,077
Targeting the PI3K pathway in cancer: are we making headway?
Janku, F., Yap, T. A., & Meric-Bernstam, F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.28 · Cited by 1,033
Targeting PI3K/mTOR Signaling in Cancer
Arcaro, A. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00084 · Cited by 1,024
Sever, R., & Brugge, J. S. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006098 · Cited by 989
PI3K signalling: the path to discovery and understanding
Vanhaesebroeck, B., Stephens, L., & Hawkins, P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3290 · Cited by 987
Essential role for nuclear PTEN in maintaining chromosomal integrity
Shen, W. H., Balajee, A. S., Wang, J., Wu, H., Eng, C., Pandolfi, P. P., & Yin, Y. (2007) · Cell · doi:10.1016/j.cell.2006.11.042 · Cited by 979
The Biology and Clinical Relevance of the PTEN Tumor Suppressor Pathway
Sansal, I., & Sellers, W. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.141 · Cited by 921
The PTEN–PI3K pathway: of feedbacks and cross-talks
Carracedo, A., & Pandolfi, P. P. (2008) · Oncogene · doi:10.1038/onc.2008.247 · Cited by 878
The PI3K/AKT Pathway as a Target for Cancer Treatment
Mayer, I. A., & Arteaga, C. L. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-062913-051343 · Cited by 822
Whitman, M., Kaplan, D. R., Schaffhausen, B., Cantley, L., & Roberts, T. M. (1985) · Nature · doi:10.1038/315239a0 · Cited by 810
Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway
Polivka, J., & Janku, F. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.12.004 · Cited by 765
Bendell, J. C., Rodon, J., Burris, H. A., de Jonge, M., Verweij, J., Birle, D., Demanse, D., De Buck, S. S., Ru, Q. C., Peters, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1360 · Cited by 684
Lucas, C. L., Kuehn, H. S., Zhao, F., Niemela, J. E., Deenick, E. K., Palendira, U., Avery, D. T., Moens, L., Cannons, J. L., Biancalana, M., et al. (2014) · Nature Immunology · doi:10.1038/ni.2771 · Cited by 673
Smith, R. A., Cokkinides, V., Brooks, D., Saslow, D., & Brawley, O. W. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20063 · Cited by 660
Clinical implications of PTEN loss in prostate cancer
Jamaspishvili, T., Berman, D. M., Ross, A. E., Scher, H. I., De Marzo, A. M., Squire, J. A., & Lotan, T. L. (2018) · Nature Reviews Urology · doi:10.1038/nrurol.2018.9 · Cited by 651
Reed, J. C. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd726 · Cited by 643
Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors
Siveen, K. S., Sikka, S., Surana, R., Dai, X., Zhang, J., Kumar, A. P., Tan, B. K. H., Sethi, G., & Bishayee, A. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.12.005 · Cited by 634
Self-citationAsati, V., Mahapatra, D. K., & Bharti, S. K. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.01.012 · Cited by 612
Lamouille, S., & Derynck, R. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200611146 · Cited by 572
The Structure of a Human p110α/p85α Complex Elucidates the Effects of Oncogenic PI3Kα Mutations
Huang, C.-H., Mandelker, D., Schmidt-Kittler, O., Samuels, Y., Velculescu, V. E., Kinzler, K. W., Vogelstein, B., Gabelli, S. B., & Amzel, L. M. (2007) · Science · doi:10.1126/science.1150799 · Cited by 560
Oncogenic PI3K and its role in cancer
Samuels, Y., & Ericson, K. (2006) · Current Opinion in Oncology · doi:10.1097/01.cco.0000198021.99347.b9 · Cited by 521
Breast Cancer–Associated PIK3CA Mutations Are Oncogenic in Mammary Epithelial Cells
Isakoff, S. J., Engelman, J. A., Irie, H. Y., Luo, J., Brachmann, S. M., Pearline, R. V., Cantley, L. C., & Brugge, J. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2612 · Cited by 509
Ohtsu, A., Ajani, J. A., Bai, Y.-X., Bang, Y.-J., Chung, H.-C., Pan, H.-M., Sahmoud, T., Shen, L., Yeh, K.-H., Chin, K., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.3552 · Cited by 483
A review on the pharmacological effects of vitexin and isovitexin
He, M., Min, J.-W., Kong, W.-L., He, X.-H., Li, J.-X., & Peng, B.-W. (2016) · Fitoterapia · doi:10.1016/j.fitote.2016.09.011 · Cited by 472
Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors
Dienstmann, R., Rodon, J., Serra, V., & Tabernero, J. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0639 · Cited by 462
Yang, J., Pi, C., & Wang, G. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.04.072 · Cited by 450
Silva, A., Yunes, J. A., Cardoso, B. A., Martins, L. R., Jotta, P. Y., Abecasis, M., Nowill, A. E., Leslie, N. R., Cardoso, A. A., & Barata, J. T. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34616 · Cited by 443
Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway
Burris, H. A. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2043-3 · Cited by 440
Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review
Costa, R. L. B., Han, H. S., & Gradishar, W. J. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4697-y · Cited by 439
PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment
Guerrero-Zotano, A., Mayer, I. A., & Arteaga, C. L. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9637-x · Cited by 417
Apoptosis-based therapies for hematologic malignancies
Reed, J. C., & Pellecchia, M. (2005) · Blood · doi:10.1182/blood-2004-07-2761 · Cited by 402
Survival of acute myeloid leukemia cells requires PI3 kinase activation
Xu, Q., Simpson, S.-E., Scialla, T. J., Bagg, A., & Carroll, M. (2003) · Blood · doi:10.1182/blood-2002-11-3429 · Cited by 394
PTEN: a new guardian of the genome
Yin, Y., & Shen, W. H. (2008) · Oncogene · doi:10.1038/onc.2008.241 · Cited by 388
Targeting arachidonic acid pathway by natural products for cancer prevention and therapy
Yarla, N. S., Bishayee, A., Sethi, G., Reddanna, P., Kalle, A. M., Dhananjaya, B. L., Dowluru, K. S. V. G. K., Chintala, R., & Duddukuri, G. R. (2016) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2016.02.001 · Cited by 364
Self-citationKordes, S., Pollak, M. N., Zwinderman, A. H., Mathôt, R. A., Weterman, M. J., Beeker, A., Punt, C. J., Richel, D. J., & Wilmink, J. W. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00027-3 · Cited by 361
Oncogenic Roles of the PI3K/AKT/mTOR axis
Aoki, M., & Fujishita, T. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_6 · Cited by 355
Bioactive natural products in cancer prevention and therapy: Progress and promise
Bishayee, A., & Sethi, G. (2016) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2016.08.006 · Cited by 354
Self-citationPI3K/Akt signaling in osteosarcoma
Zhang, J., Yu, X.-H., Yan, Y.-G., Wang, C., & Wang, W.-J. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.12.041 · Cited by 327
Zhao, J. J., Liu, Z., Wang, L., Shin, E., Loda, M. F., & Roberts, T. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508988102 · Cited by 324
Targeting autophagy using natural compounds for cancer prevention and therapy
Deng, S., Shanmugam, M. K., Kumar, A. P., Yap, C. T., Sethi, G., & Bishayee, A. (2019) · Cancer · doi:10.1002/cncr.31978 · Cited by 320
Self-citationXenohormesis: Sensing the Chemical Cues of Other Species
Howitz, K. T., & Sinclair, D. A. (2008) · Cell · doi:10.1016/j.cell.2008.04.019 · Cited by 301
Burke, J. E., Perisic, O., Masson, G. R., Vadas, O., & Williams, R. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205508109 · Cited by 300
Barata, J. T., Silva, A., Brandao, J. G., Nadler, L. M., Cardoso, A. A., & Boussiotis, V. A. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040789 · Cited by 284
The PI3K AKT pathway in the pathogenesis of prostate cancer
Wen, X. (2016) · Frontiers in Bioscience · doi:10.2741/4443 · Cited by 283
Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer
Gao, N., Zhang, Z., Jiang, B.-H., & Shi, X. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.09.132 · Cited by 275
Ferraldeschi, R., Nava Rodrigues, D., Riisnaes, R., Miranda, S., Figueiredo, I., Rescigno, P., Ravi, P., Pezaro, C., Omlin, A., Lorente, D., et al. (2015) · European Urology · doi:10.1016/j.eururo.2014.10.027 · Cited by 268
Functional proteomic profiling of AML predicts response and survival
Kornblau, S. M., Tibes, R., Qiu, Y. H., Chen, W., Kantarjian, H. M., Andreeff, M., Coombes, K. R., & Mills, G. B. (2009) · Blood · doi:10.1182/blood-2007-10-119438 · Cited by 263
Narayanankutty, A. (2019) · Current Drug Targets · doi:10.2174/1389450120666190618123846 · Cited by 255
King, D., Yeomanson, D., & Bryant, H. E. (2015) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000000329 · Cited by 248
Hortobagyi, G. N., Chen, D., Piccart, M., Rugo, H. S., Burris, H. A., Pritchard, K. I., Campone, M., Noguchi, S., Perez, A. T., Deleu, I., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.1971 · Cited by 248
Schwartz, S., Wongvipat, J., Trigwell, C. B., Hancox, U., Carver, B. S., Rodrik-Outmezguine, V., Will, M., Yellen, P., de Stanchina, E., Baselga, J., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.008 · Cited by 246
Targeting PI3K/AKT/mTOR network for treatment of leukemia
Bertacchini, J., Heidari, N., Mediani, L., Capitani, S., Shahjahani, M., Ahmadzadeh, A., & Saki, N. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1867-5 · Cited by 243
Shanmugam, M. K., Lee, J. H., Chai, E. Z. P., Kanchi, M. M., Kar, S., Arfuso, F., Dharmarajan, A., Kumar, A. P., Ramar, P. S., Looi, C. Y., et al. (2016) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2016.03.005 · Cited by 230
Self-citationThe Genomic Landscape of Breast Cancer as a Therapeutic Roadmap
Ellis, M. J., & Perou, C. M. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0462 · Cited by 229
PI3K inhibitors as new cancer therapeutics: implications for clinical trial design
Massacesi, C., Di Tomaso, E., Urban, P., Germa, C., Quadt, C., Trandafir, L., Aimone, P., Fretault, N., Dharan, B., Tavorath, R., et al. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s89967 · Cited by 229
Ruiz-Torres, V., Encinar, J., Herranz-López, M., Pérez-Sánchez, A., Galiano, V., Barrajón-Catalán, E., & Micol, V. (2017) · Molecules · doi:10.3390/molecules22071037 · Cited by 229
Novel Small Molecule Inhibitors of 3-Phosphoinositide-dependent Kinase-1
Feldman, R. I., Wu, J. M., Polokoff, M. A., Kochanny, M. J., Dinter, H., Zhu, D., Biroc, S. L., Alicke, B., Bryant, J., Yuan, S., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501367200 · Cited by 228
Phosphoinositide 3-Kinase Signalling Pathways in Tumor Progression, Invasion and Angiogenesis
Brader, S., & Eccles, S. A. (2004) · Tumori Journal · doi:10.1177/030089160409000102 · Cited by 216
Targeting the PI3K signaling pathway in cancer therapy
Bartholomeusz, C., & Gonzalez-Angulo, A. M. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.644788 · Cited by 216
Baek, S. H., Ko, J., Lee, J. H., Kim, C., Lee, H., Nam, D., Lee, J., Lee, S., Yang, W. M., Um, J., et al. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25426 · Cited by 207
Tewari, D., Nabavi, S. F., Nabavi, S. M., Sureda, A., Farooqi, A. A., Atanasov, A. G., Vacca, R. A., Sethi, G., & Bishayee, A. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2017.09.014 · Cited by 205
Self-citationChamcheu, J., Roy, T., Uddin, M., Banang-Mbeumi, S., Chamcheu, R.-C., Walker, A., Liu, Y.-Y., & Huang, S. (2019) · Cells · doi:10.3390/cells8080803 · Cited by 196
Min, Y. H., Eom, J. I., Cheong, J. W., Maeng, H. O., Kim, J. Y., Jeung, H. K., Lee, S. T., Lee, M. H., Hahn, J. S., & Ko, Y. W. (2003) · Leukemia · doi:10.1038/sj.leu.2402874 · Cited by 192
Managing the changing burden of cancer in Asia
Sankaranarayanan, R., Ramadas, K., & Qiao, Y.-L. (2014) · BMC Medicine · doi:10.1186/1741-7015-12-3 · Cited by 186
PI3K/Akt/mTOR inhibitors in breast cancer
Joycelyn, Jx, Lee, Kiley, Loh, K. W.-J., Yoon-Sim, & Yap (2015) · 癌症生物学与医学:英文版 · Cited by 185
Wegiel, B., Bjartell, A., Culig, Z., & Persson, J. L. (2008) · International Journal of Cancer · doi:10.1002/ijc.23261 · Cited by 179
Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?
Singh, S. S. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i43.12261 · Cited by 179
Soria, J.-C., Shepherd, F. A., Douillard, J.-Y., Wolf, J., Giaccone, G., Crino, L., Cappuzzo, F., Sharma, S., Gross, S. H., Dimitrijevic, S., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp060 · Cited by 163
Smith, M., Barnett, M., Bassan, R., Gatta, G., Tondini, C., & Kern, W. (2004) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2003.11.002 · Cited by 162
Ong, P. S., Wang, L. Z., Dai, X., Tseng, S. H., Loo, S. J., & Sethi, G. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00395 · Cited by 162
Curcumin inhibits proliferation of colorectal carcinoma by modulating Akt/mTOR signaling.
Johnson, S. M., Gulhati, P., Arrieta, I., Wang, X., Uchida, T., Gao, T., & Evers, B. M. (2009) · PubMed · Cited by 161
Status of PI3K inhibition and biomarker development in cancer therapeutics
Markman, B., Atzori, F., Pérez-García, J., Tabernero, J., & Baselga, J. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp347 · Cited by 159
Siveen, K. S., Ahn, K. S., Ong, T. H., Shanmugam, M. K., Li, F., Yap, W. N., Kumar, A. P., Fong, C. W., Tergaonkar, V., Hui, K. M., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1876 · Cited by 153
O’Hare, T., Deininger, M. W., Eide, C. A., Clackson, T., & Druker, B. J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3314 · Cited by 150
Thomas, C., Lamoureux, F., Crafter, C., Davies, B. R., Beraldi, E., Fazli, L., Kim, S., Thaper, D., Gleave, M. E., & Zoubeidi, A. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0032 · Cited by 147
Yip, P. Y. (2015) · PubMed · doi:10.3978/j.issn.2218-6751.2015.01.04 · Cited by 144
Toward rapamycin analog (rapalog)-based precision cancer therapy
Meng, L., & Zheng, X. F. S. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2015.68 · Cited by 141
Shanmugam, M. K., Ong, T. H., Kumar, A. P., Lun, C. K., Ho, P. C., Wong, P. T. ‐., Hui, K. M., & Sethi, G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032476 · Cited by 134
Liu, X., Jiang, Q., Liu, H., & Luo, S. (2019) · Biological Research · doi:10.1186/s40659-019-0214-y · Cited by 130
Seront, E., Rottey, S., Sautois, B. R., Kerger, J. N., D'Hondt, L. A., Verschaeve, V., Canon, J. L., Dopchie, C., Vandenbulcke, J., Whenham, N., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds057 · Cited by 129
Loss of PTEN expression leading to high Akt activation in human multiple myelomas
Hyun, T. S., Yam, A., Pece, S., Xie, X., Zhang, J., Miki, T., Gutkind, J. S., & Li, W. (2000) · Blood · doi:10.1182/blood.v96.10.3560 · Cited by 127
Fan, X., Wang, Y., Wang, L., & Zhu, M. (2016) · Oncology Reports · doi:10.3892/or.2016.5138 · Cited by 127
Antioxidative and in vitro antiproliferative activity of Arctium lappa root extracts
Predes, F. D. S., Ruiz, A. L. T. G., de Carvalho, J. E., Foglio, M. A., & Dolder, H. (2011) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-11-25 · Cited by 125
Outlook on PI3K/AKT/mTOR inhibition in acute leukemia
Fransecky, L. R., Mochmann, L. H., & Baldus, C. D. (2015) · Molecular and Cellular Therapies · doi:10.1186/s40591-015-0040-8 · Cited by 125
Silva, A., Gírio, A., Cebola, I., Santos, C. I., Antunes, F., & Barata, J. T. (2011) · Leukemia · doi:10.1038/leu.2011.56 · Cited by 123
Targeting the PI3K/AKT/mTOR Signaling Axis in Children with Hematologic Malignancies
Barrett, D., Brown, V. I., Grupp, S. A., & Teachey, D. T. (2012) · Pediatric Drugs · doi:10.1007/bf03262236 · Cited by 123
Martelli, A. M., Chiarini, F., Evangelisti, C., Cappellini, A., Buontempo, F., Bressanin, D., Fini, M., & McCubrey, J. A. (2012) · Oncotarget · doi:10.18632/oncotarget.477 · Cited by 123
Tamburini, J., Elie, C., Bardet, V., Chapuis, N., Park, S., Broët, P., Cornillet-Lefebvre, P., Lioure, B., Ugo, V., Blanchet, O., et al. (2007) · Blood · doi:10.1182/blood-2006-12-061283 · Cited by 120
Natural products: a hope for glioblastoma patients
Vengoji, R., Macha, M. A., Batra, S. K., & Shonka, N. (2018) · Oncotarget · doi:10.18632/oncotarget.25175 · Cited by 120
Targeting the PI3K/Akt/mTOR Axis by Apigenin for Cancer Prevention
Tong, X., & Pelling, J. C. (2013) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/18715206113139990119 · Cited by 119
PI3K Inhibitors: Understanding Toxicity Mechanisms and Management.
Greenwell, I. B., Ip, A., & Cohen, J. B. (2017) · PubMed · Cited by 119
Parikh, N. R., Mandal, A., Bhatia, D., Siveen, K. S., Sethi, G., & Bishayee, A. (2014) · Phytochemistry Reviews · doi:10.1007/s11101-014-9337-5 · Cited by 117
Self-citationShinde, A., Hardy, S. D., Kim, D., Akhand, S. S., Jolly, M. K., Wang, W.-H., Anderson, J. C., Khodadadi, R. B., Brown, W. S., George, J. T., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2636 · Cited by 115
Inhibition of PI3K/Akt Signaling: An Emerging Paradigm for Targeted Cancer Therapy
Chen, Y., Law, P. C., & Loh, H. H. (2005) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/156801105774574649 · Cited by 113
Anti-apoptotic BCL-2 family proteins in acute neural injury
Anilkumar, U., & Prehn, J. H. M. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00281 · Cited by 112
Kumar, S., & Agnihotri, N. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.182 · Cited by 111
Hao, Y., Wang, C., Cao, B., Hirsch, B. M., Song, J. K., Markowitz, S. D., Ewing, R. M., Sedwick, D., Liu, L., Zheng, W., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.03.021 · Cited by 110
Chen, W., Drakos, E., Grammatikakis, I., Schlette, E. J., Jiang, L., Leventaki, V., Staikou-Drakopoulou, E., Patsouris, E., Panayiotidis, P. G., Medeiros, L. J., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-292 · Cited by 110
Porta, C., & Figlin, R. A. (2009) · The Journal of Urology · doi:10.1016/j.juro.2009.08.085 · Cited by 110
Adverse drug reactions of anticancer drugs derived from natural sources
Tewari, D., Rawat, P., & Singh, P. K. (2018) · Food and Chemical Toxicology · doi:10.1016/j.fct.2018.11.041 · Cited by 110
Self-citationNatural Products Targeting Autophagy via the PI3K/Akt/mTOR Pathway as Anticancer Agents
Sun, H. Y., Wang, Z., & Yakisich, J. S. (2013) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/18715206113139990130 · Cited by 107
Marques, R. B., Aghai, A., de Ridder, C. M. A., Stuurman, D. C., Hoeben, S. A. H., Boer, A., Ellston, R. P. A., Barry, S. T., Davies, B. R., Trapman, J., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.08.053 · Cited by 106
Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology
Curigliano, G., & Shah, R. R. (2019) · Drug Safety · doi:10.1007/s40264-018-0778-4 · Cited by 106
Hiraiwa, M., Taylor, E. M., Campana, W. M., Darin, S. J., & O’Brien, J. S. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4778 · Cited by 103
Nyåkern, M., Tazzari, P. L., Finelli, C., Bosi, C., Follo, M. Y., Grafone, T., Piccaluga, P. P., Martinelli, G., Cocco, L., & Martelli, A. M. (2005) · Leukemia · doi:10.1038/sj.leu.2404057 · Cited by 99
TGF-β/PI3K/AKT/mTOR/NF-kB pathway. Clinicopathological features in prostate cancer
Torrealba, N., Vera, R., Fraile, B., Martínez-Onsurbe, P., Paniagua, R., & Royuela, M. (2019) · The Aging Male · doi:10.1080/13685538.2019.1597840 · Cited by 99
Armstrong, A. J., Halabi, S., Healy, P. N., Alumkal, J. J., Winters, C., Kephart, J. J. G., Bitting, R. L., Hobbs, C. A., Soleau, C., Beer, T. M., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.02.030 · Cited by 98
Campana, W. M., Hiraiwa, M., & O’Brien, J. S. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.03.307 · Cited by 97
Regulation of epithelial-mesenchymal transition and metastasis by TGF-β, P-bodies, and autophagy
Hardy, S. D., Shinde, A. B., Wang, W., Wendt, M. K., & Geahlen, R. L. (2017) · Oncotarget · doi:10.18632/oncotarget.21871 · Cited by 96
Oh, D., Kim, T., Park, Y. S., Shin, S. J., Shin, S. H., Song, E., Lee, H. J., Lee, K., & Bang, Y. (2012) · Cancer · doi:10.1002/cncr.27675 · Cited by 95
PIM Kinases and Their Relevance to the PI3K/AKT/mTOR Pathway in the Regulation of Ovarian Cancer
Aziz, A. U. R., Farid, S., Qin, K., Wang, H., & Liu, B. (2018) · Biomolecules · doi:10.3390/biom8010007 · Cited by 95
Sánchez, B. G., Bort, A., Mateos‐Gómez, P. A., Rodríguez‐Henche, N., & Díaz‐Laviada, I. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0769-2 · Cited by 95
Autocrine Fibronectin Inhibits Breast Cancer Metastasis
Shinde, A. B., Libring, S., Alpsoy, A., Abdullah, A., Schaber, J. A., Solorio, L., & Wendt, M. K. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0151 · Cited by 93
Jiang, J., Pi, J., Jin, H., & Cai, J. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27654 · Cited by 93
Harashima, N., Inao, T., Imamura, R., Okano, S., Suda, T., & Harada, M. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1132-1 · Cited by 90
Li, T., & Wang, G. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms151018856 · Cited by 87
Grifolin induces apoptosis via inhibition of PI3K/AKT signalling pathway in human osteosarcoma cells
Jin, S., Pang, R., Shen, J.-N., Huang, G., Wang, J., & Zhou, J. (2007) · APOPTOSIS · doi:10.1007/s10495-007-0062-z · Cited by 84
Wang, F., Ma, H., Liu, Z., Huang, W., Xu, X., & Zhang, X. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.05.129 · Cited by 84
Zhang, L., Chen, C., Duanmu, J., Wu, Y., Tao, J., Yang, A., Yin, X., Xiong, B., Gu, J., Li, C., et al. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.10.035 · Cited by 83
mTOR signaling in osteosarcoma: Oncogenesis and therapeutic aspects (Review)
Hu, K., Dai, H.-B., & Qiu, Z.-L. (2016) · Oncology Reports · doi:10.3892/or.2016.4922 · Cited by 82
Yu, Y., Wu, X., Pu, J., Luo, P., Ma, W., Wang, J., Wei, J., Wang, Y., & Fei, Z. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.11.165 · Cited by 79
Yang, M. H., Lee, J. H., Ko, J., Jung, S. H., Sethi, G., & Ahn, K. S. (2019) · Molecules · doi:10.3390/molecules24081584 · Cited by 78
Medicinal Plants and Natural Products Used in Cataract Management
Tewari, D., Samoilă, O., Gocan, D., Mocan, A., Moldovan, C., Devkota, H. P., Atanasov, A. G., Zengin, G., Echeverría, J., Vodnar, D. C., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00466 · Cited by 74
Self-citationAiriau, K., Mahon, F., Josselin, M., Jeanneteau, M., & Belloc, F. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.309 · Cited by 73
Popolo, A., Pinto, A., Daglia, M., Nabavi, S. F., Farooqı, A. A., & Rastrelli, L. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.06.002 · Cited by 69
Moreno, C. S. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090657 · Cited by 67
Tewari, D., Mocan, A., Parvanov, E. D., Sah, A. N., Nabavi, S. M., Huminiecki, Ł., Feei, Z., Lee, Y. Y., Horbańczuk, J. O., & Atanasov, A. G. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00519 · Cited by 67
Self-citationCrosstalk between NOTCH and AKT signaling during murine megakaryocyte lineage specification
Cornejo, M., Mabialah, V., Sykes, S. M., Khandan, T., Celso, C. L., Lopez, C. K., Rivera-Muñoz, P., Rameau, P., Tóthová, Z., Aster, J. C., et al. (2011) · Blood · doi:10.1182/blood-2011-01-328567 · Cited by 65
Editorial (Hot Topic: Inhibition of PI3K/Akt/mTOR Signaling by Natural Products)
Huang, S. (2013) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520611313070001 · Cited by 63
Brown, V. I., Hulitt, J., Fish, J. D., Sheen, C., Bruno, M., Xu, Q., Carroll, M. P., Fang, J., Teachey, D. T., & Grupp, S. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4704 · Cited by 62
Kim, S. W., Kim, S., Bae, H., Nam, D., Lee, J., Lee, S., Shim, B. S., Kim, S., Ahn, K. S., Choi, S., et al. (2012) · The Prostate · doi:10.1002/pros.22574 · Cited by 61
Gunadharini, D. N., Perumal, E., Arunkumar, R., Senthilkumar, K., & Arunakaran, J. (2011) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2011.01.015 · Cited by 60
Targeting the PI3K Pathway for Cancer Therapy
Sadeghi, N., & Gerber, D. E. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.56 · Cited by 60
He, H., Zeng, Q., Huang, G., Lin, Y., Lin, H., Liu, W., & Lu, P. (2018) · Brain Research · doi:10.1016/j.brainres.2018.11.018 · Cited by 60
Wang, H., Duan, L., Zou, Z., Li, H., Yuan, S., Chen, X., Zhang, Y., Li, X., Sun, H., Zha, H., et al. (2014) · International Journal of Medical Sciences · doi:10.7150/ijms.8128 · Cited by 57
Zabkiewicz, J., Pearn, L., Hills, R. K., Morgan, G., Tonks, A., Burnett, A. K., & Darley, R. L. (2013) · Haematologica · doi:10.3324/haematol.2013.096487 · Cited by 56
Wu, C., Qiu, S.-L., Liu, P., Ge, Y.-Q., & Gao, X.-F. (2018) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2017.09.033 · Cited by 56
Human papillomavirus and risk of prostate cancer: a systematic review and meta-analysis
Russo, G. I., Calogero, A. E., Condorelli, R. A., Scalia, G., Morgia, G., & Vignera, S. L. (2018) · The Aging Male · doi:10.1080/13685538.2018.1455178 · Cited by 55
Jing, X., Peng, J., Dou, Y., Sun, J., Ma, C., Wang, Q., Zhang, L., Luo, X., Kong, B., Zhang, Y., et al. (2019) · Immunology and Cell Biology · doi:10.1111/imcb.12245 · Cited by 55
Characterization of a Tumor-Associated Activating Mutation of the p110β PI 3-Kinase
Dbouk, H. A., Khalil, B. D., Wu, H., Shymanets, A., Nürnberg, B., & Backer, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063833 · Cited by 54
Cucurbitacin I induces pro‐death autophagy in A549 cells via the ERK‐mTOR‐STAT3 signaling pathway
Ni, Y., Wu, S., Wang, X., Zhu, G., Chen, X., Ding, Y., & Jiang, W. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26808 · Cited by 53
Zhu, J., Sun, Y., Lü, Y., Jiang, X., Ma, B., Yu, L., Zhang, J., Dong, X., & Zhang, Q. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0684-9 · Cited by 53
White, D. A., Schwartz, L. H., Dimitrijević, S., et al. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181ba20b1 · Cited by 52
Kushner, B. H., Cheung, N. V., Modak, S. I., Becher, O. J., Basu, E. M., Roberts, S. S., Kramer, K., & Dunkel, I. J. (2016) · International Journal of Cancer · doi:10.1002/ijc.30440 · Cited by 52
Arctigenin inhibits prostate tumor cell growth in vitro and in vivo
Wang, P., Solorzano, W. M., Diaz, T., Magyar, C. E., Henning, S. M., & Vadgama, J. V. (2017) · Clinical Nutrition Experimental · doi:10.1016/j.yclnex.2017.04.001 · Cited by 50
Hossan, M. S., Chan, Z.-Y., Collins, H. M., Shipton, F. N., Butler, M. S., Rahmatullah, M., Lee, J. B., Gershkovich, P., Kagan, L., Khoo, T.-J., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.03.034 · Cited by 50
Yang, L., Liu, Y., Wang, M., Qian, Y., Dai, X., Zhu, Y., Chen, J., Guo, S., & Hisamitsu, T. (2016) · Oncology Letters · doi:10.3892/ol.2016.5213 · Cited by 49
Axanova, L. S., Chen, Y. Q., McCoy, T. P., Sui, G., & Cramer, S. D. (2010) · The Prostate · doi:10.1002/pros.21201 · Cited by 48
Rosenberg, L. M., Yoon, C. H., Sharma, G., et al. (2018) · Carcinogenesis · doi:10.1093/carcin/bgy038 · Cited by 48
Núñez, C. D. B., Cansino, J. R., de Bethencourt, F. R., Pérez-Utrilla, M., Fraile, B., Martínez-Onsurbe, P., Olmedilla, G., Paniagua, R., & Royuela, M. (2008) · Histopathology · doi:10.1111/j.1365-2559.2008.03092.x · Cited by 47
Jian, M., Yunjia, Z., Ding, Z., Yanduo, J., & Guocheng, J. (2018) · Molecular Carcinogenesis · doi:10.1002/mc.22933 · Cited by 46
Kim, G., Cheong, O., Bae, S. Y., Shin, J., & Lee, S. K. (2013) · Marine Drugs · doi:10.3390/md11041087 · Cited by 44
Sachan, R., Kundu, A. B., Jeon, Y., Choi, W. S., Yoon, K., Kim, I. S., Kwak, J. H., & Kim, H. S. (2018) · Phytomedicine · doi:10.1016/j.phymed.2018.10.012 · Cited by 43
Okabe, S., Tauchi, T., Tanaka, Y., Kitahara, T., Kimura, S. H., Maekawa, T., & Ohyashiki, K. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.26725 · Cited by 42
Lee, T.-J., Sartor, O. A., Luftig, R. B., & Koochekpour, S. (2004) · Molecular Cancer · doi:10.1186/1476-4598-3-31 · Cited by 41
LINC00968 functions as an oncogene in osteosarcoma by activating the PI3K/AKT/mTOR signaling
Liu, G., Yuan, D., Sun, P., Liu, W., Wu, P., Liu, H., & Yu, G. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26624 · Cited by 41
Ramos-Peñafiel, C. O., Olarte-Carrillo, I., Maldonado, R. C., Rozen‐Fuller, E., Kassack-Ipiña, J. J., Meléndez, G., Collazo-Jaloma, J., & Martínez‐Tovar, A. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1620-6 · Cited by 41
Tang, Y.-Q., Jaganath, I. B., Manikam, R., & Sekaran, S. D. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/609581 · Cited by 40
How can molecular abnormalities influence our clinical approach
Wei, W., Giulia, F. M., Luffer, S., Kumar, R., Wu, B., Tavallai, M., Bekele, R., & Birrer, M. J. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx447 · Cited by 40
Molina‐Garrido, M., & Guillén‐Ponce, C. (2017) · The Aging Male · doi:10.1080/13685538.2016.1277516 · Cited by 37
Li, X., Tang, Y., Yu, F., Sun, Y., Huang, F., Chen, Y., Yang, Z., & Ding, G. (2018) · Marine Drugs · doi:10.3390/md16090325 · Cited by 37
Wu, T., Dong, X., Yu, D., Shen, Z., Yu, J., & Yan, S. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s186186 · Cited by 37
Uchida, A., Seki, N., Mizuno, K., Yamada, Y., Misono, S., Sanada, H., Kikkawa, N., Kumamoto, T., Suetsugu, T., & Inoue, H. (2019) · Cancers · doi:10.3390/cancers11020258 · Cited by 36
Li, Y., Song, X., Liu, Z., Li, Q., Huang, M., Su, B., Mao, Y., Wang, Y., Mo, W., & Chen, H. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00298 · Cited by 36
Pan, Y., Shi, J., Ni, W., Liu, Y., Wang, S., Wang, X., Wei, Z., Wang, A., Chen, W., & Lu, Y. (2017) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13135 · Cited by 35
Castro‐Falcón, G., Seiler, G. S., Demir, Ö., Rathinaswamy, M. K., Hamelin, D. J., Hoffmann, R. M., Makowski, S. L., Letzel, A., Field, S. J., Burke, J. E., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00975 · Cited by 34
From the Bench to the Bed Side: PI3K Pathway Inhibitors in Clinical Development
Maira, S.-M., Finan, P. M., & García-Echeverría, C. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_60 · Cited by 33
Roy, G., Guan, S., Liu, H., & Zhang, L. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00545 · Cited by 32
Casanova, I., Bosch, R., Lasa, A., Parreño, M., Céspedes, M. V., Brunet, S., Nomdedeu, J. F., Mangues, M. A., Sierra, J., & Mangues, R. (2008) · International Journal of Cancer · doi:10.1002/ijc.23516 · Cited by 29
CXCL8 promotes the invasion of human osteosarcoma cells by regulation of PI3K/Akt signaling pathway
Jiang, H., Wang, X., Miao, W., Wang, B., & Qiu, Y. (2017) · Apmis · doi:10.1111/apm.12721 · Cited by 28
PI3K pathway and Bcl-2 family. Clinicopathological features in prostate cancer
Torrealba, N., Rodríguez‐Berriguete, G., Fraile, B., Olmedilla, G., Martínez-Onsurbe, P., Sánchez‐Chapado, M., Paniagua, R., & Royuela, M. (2018) · The Aging Male · doi:10.1080/13685538.2018.1424130 · Cited by 27
Ma, L., Meng, Y., Tu, C., Cao, X., Wang, H., Li, Y., Man, S., Zhou, J., Li, M., Liu, Z., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.09.019 · Cited by 27
Lai, H., Wang, Y., Duan, F., Li, Y., Jiang, Z., Luo, L., Liu, L., Leung, E. L., & Yao, X. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00958 · Cited by 26
Cited by
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
Ischemia-reperfusion injury: molecular mechanisms and therapeutic targets
Zhang, M., Liu, Q., Meng, H., Duan, H., Liu, X., Wu, J., Gao, F., Wang, S., Tan, R., & Yuan, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01688-x · Cited by 712
Cell-cell communication: New insights and clinical implications
Su, J., Song, Y., Zhu, Z., Huang, X., Fan, J., Qiao, J., & Mao, F. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01888-z · Cited by 433
Recent advances in targeted strategies for triple-negative breast cancer
Zhu, S., Wu, Y., Song, B., Yi, M., Yan, Y., Mei, Q., & Wu, K. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01497-3 · Cited by 331
Curcumin Formulations for Better Bioavailability: What We Learned from Clinical Trials Thus Far?
Hegde, M., Girisa, S., BharathwajChetty, B., Vishwa, R., & Kunnumakkara, A. B. (2023) · ACS Omega · doi:10.1021/acsomega.2c07326 · Cited by 301
Metadata
- Authors
- Tewari, D., Patni, P., Bishayee, A., Sah, A. N., & Bishayee, A.
- Venue
- Seminars in Cancer Biology
- Publisher
- Elsevier BV
- Published
- 2022-05
- Volume
- 80
- Pages
- 1-17
- ISSN
- 1044-579X (ISSN-L)
- OpenAlex
- W2995204555
- Cited by
- 642
- References
- 212
- FWCI
- 9.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.